YM155 (Sepantronium Bromide)

Catalog No.S1130

YM155 (Sepantronium Bromide) Chemical Structure

Molecular Weight(MW): 443.29

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 41 Publications

12 Customer Reviews

  • Dose response of ALL cell lines to YM155. Asynchronous populations of cells were treated with increasing doses of YM155 for 72 h. Then, viability was measured by MTS and normalized to no drug control. S.e.m. bars are inserted. Dotted line represents 50% viability.

    Leukemia 2012 26, 623-632. YM155 (Sepantronium Bromide) purchased from Selleck.

    Treatment of SUPB15 cells with imatinib or YM155. Top panel shows cells treated with siRNA in the presence of 500 nM imatinib. Cells were treated with siRNA, and then subsequently incubated in 500 nM imatinib for 96 h. Bottom panel shows the partial rescue of SUPB15 cells treated with 100 nM YM155 for 96 h. S.e.m. bars are inserted into each graph.

    Leukemia 2012 26, 623-632. YM155 (Sepantronium Bromide) purchased from Selleck.

  • Inhibition of survivin expression restricts VZV repl ication and sprea d in vitro . ( A ) HEL F were infected w ith VZV-GFP in the presence of YM155 or DMSO, and infectious virus yields were determined at 48 hpi by titration on melanoma cells. ( B) VZV-GFP-infected HELF were treated with DMSO or YM155; plaques were detected by staining with anti-VZV IgG at 48 hpi. Plaque sizes were determined using ImageJ; the graph shows the mean size ?S EM o f 30 plaques . (C )Expression of VZV proteins was assessed in VZV-infected HELF lysat e s (24 hp i) treated with YM155 or DMSO.

    Proc Natl Acad Sci U S A 2012 109, 600-5. YM155 (Sepantronium Bromide) purchased from Selleck.

    MM cell lines UM9 (left panel) or U266 (right panel) were cultured in presence or absence of accessory cells prior to incubation with CTLs alone, YM155 alone or the combination. Survival of UM9 and U266 MM cells was assessed by CS-BLI. Results show % lysis of MM cells after 24 hour incubation and are depicted for three doses.

    Clin Cancer Res 2013 19, 5591-601. YM155 (Sepantronium Bromide) purchased from Selleck.

  • Survivin inhibitor increased apoptosis in burn serum-stimulated cardiomyocytes. a YM155 increased apoptosis in burn serumstimulated cardiomyocytes in a concentration-dependent manner. Neonatal rat cardiomyocytes were treated with YM155 (3-300 nM at the indicated) for 2 h prior to stimulation burn serum for 12 h. The extent of DNA fragmentation was quantified using the Cell Death Detection ELISA. versus 0 nM YM155 plus stimulation with burn serum. b YM155 (100 nM) pretreatment increased the apoptosis production at 2 or 12 h after burn serum stimulation. c Representative blots of survivin and cleaved caspase-3 in YM155 (100 nM) pretreated cardiomyocytes at 2 and 12 h after burn serum stimulation. d Bar graphs show the relative proteins.

    Basic Res Cardiol 2011 106, 1207-1220. YM155 (Sepantronium Bromide) purchased from Selleck.

    Induction of cardiomyocytes apoptosis by survivin inhibitor in vivo. After YM155 was administered (5 mg/kg/day) for 5 days, the rats were exposed to a 40% TBSA burn (burn injury) or 25C water (sham) and killed 6 h after burn injury. The frozen sections of the ventricular tissues or whole cell lysates were prepared. Apoptotic staining was performed using the TUNEL method and immunostained using a-sarcomeric actin. The survivin and cleaved caspase-3 levels were measured by Western blot analysis. a Representative blots of survivin and cleaved caspase-3. b The statistical analysis of the relative proteins .c Figures are representative of two independent TUNEL experiments. Green fluorescence represents apoptotic cells, whereas red stain indicates staining for a-sarcomeric actin specific for cardiac myocytes. d Bar graph summarizes the counted apoptotic cells.

     

     

    Basic Res Cardiol 2011 106, 1207-1220. YM155 (Sepantronium Bromide) purchased from Selleck.

  • YM-155 sensitizes ABT-263-induced apoptosis in HCC cells. A. LH86 and B. Huh7 cells were untreated or treated with ABT-263(1 μM), YM-155(1 μM) or combination of ABT-263(1 μM) and YM-155(1 μM) for up to 6 h. Then apoptotic cells were assessed as in Figure 2A and2B (representative apoptotic cells were marked with white arrows). C. LH86 and D. Huh7 cells were untreated or treated with ABT-263(1 μM), YM-155(1 μM) or combination of ABT-263(1 μM) and YM-155(1 μM) for 6 h. Cells with apoptotic nuclei were counted to determine cell death ratio (*p<0.05, **p<0.05). E. LH86 cells and F. Huh7 cells were treated as indicated and cell lysates were prepared and subjected to Western blotting.Apoptosis was evaluated through caspase 3 activation. b-actin was used as an equal protein loading control. G. LH86 cells grown in six-well plate were untreated (control) or treated with different conditions as indicated for 48 h. After rinsed with fresh culture medium for 3 times, cells were cultured for another two weeks. Cell colony formation assays were performed with crystal violet staining. H. colony number were counted to show combination treatment with ABT-263 and YM-155 resulted in reduction of clonogenesis (#p<0.05).

    PLoS One 2011 6, e21980. YM155 (Sepantronium Bromide) purchased from Selleck.

    Survivin down-regulation sensitizes ABT-263-induced apoptosis in HCC cells. A. LH86 cells were treated as indicated and cell lysates were prepared for Western blotting. Pro-apoptotic proteins: Bax, Bad, and Bak and anti-apoptotic proteins Bcl-xL and Mcl-1 were assessed with specific antibodies respectively. b-actin was detected and served as an equal protein loading control. B. LH86 cells were untreated or treated with ABT-263 (1 μM), YM-155 (1 μM) or combination of ABT-263 (1 μM) and YM155 (1 μM) for up to 6 h as indicated. Then cells were harvested and cell lysates were prepared for Western blotting. Anti-survivin and anti-Bcl-xL polyclonal antibodies were used to assess protein levels for survivin and Bcl-xL respectively. b-actin was used as an equal protein loading control. The band intensities of survivin, Bcl-xL, and b-actin was qualified with Image J software. C. LH86 cells were transiently transfected with synthesized random siRNA (control) or survivin specific siRNA duplexes, and 48 h posttransfection, cells were subjected to Western blotting analysis with anti-survivin polyclonal antibody. β-actin was used as an equal protein loading control. D. LH86 cells were transfected with synthesized random control siRNA or survivin specific siRNA, and 48 h post-transfection, cells were untreated or treated with ABT-263 (1 μM) for 24 h and then subjected to Hoechst staining to show apoptotic cells with condensed nuclei (representative apoptotic cells were marked with white arrows). E. LH86 cells were treated as in Figure 4D and apoptosis was measured as in Figure 2A. Statistical analysis was performed for apoptosis ratio by counting the number of cells with apoptotic nuclei (*p<0.05). F. LH86 cells treated as in Figure 4D were harvested and cell lysates were prepared and subjected to Western blotting. Apoptosis was determined through caspase 3 activation. β-actin was used as an equal protein loading control.

    PLoS One 2011 6, e21980. YM155 (Sepantronium Bromide) purchased from Selleck.

  • Effects of YM155 on cell viability (A) and cell cycle (B), and on experiment of survivin mRNA (C) and protein (D) in the MiaPaCa-2 human pancreatic cancer cell line.

    Anticancer Res 2012 32, 1681-8. YM155 (Sepantronium Bromide) purchased from Selleck.

     

    IPF fibroblasts from 8 different patients were cultured to 60% confluence in DMEM supplemented with 10% fetal bovine serum and growth-arrested for 24 hours in serum-free DMEM prior to treatment for 16 hours with/without the Fas-activating antibody CH11 (FasL; 250 ng/ml) in the presence/absence of the survivin inhibitors CAY10625 (5 µM) or YM155 (10.0 µM), or with the survivin inhibitors alone. (a) Apoptosis was assessed using ELISA-based detection of histone associated DNA fragments. To allow relative comparisons of apoptosis across experiments, the data for each cell line is expressed as the percentage of the assay positive control that was included on each ELISA plate. The scatter plot shows the distribution of responses in individual cell lines along with the mean ± standard error for each treatment group. p = 0.038 overall (ANOVA). p = 0.027 for FasL compared to FasL/CAY10625, and p = 0.046 for FasL compared to FasL/YM155; (b) The correlation of apoptosis between IPF fibroblasts treated with FasL/CAY10625 and FasL/YM155. Each point represents a different IPF cell line. The Spearman correlation (r) = 0.95.
     

    Adv Biosci Biotechnol 2012 3, 657-664. YM155 (Sepantronium Bromide) purchased from Selleck.

  • Total RNA from livers of these mice were isolated from tissues using TRIZOL (Invitrogen). cDNA synthesis was performed with the M-MLV RTase cDNA Synthesis Kit (Promega). qRT-PCR reactions were performed using SYBR Green (Takara) on ABI 7500 Fast system. Expression levels of Survivin gene were measured by qRT-PCR in livers injected with 0.9% Nacl (91#,92#) or YM155 48 hours after DEN treatment.

    Lihua Min of Chinese Academy of Sciences. YM155 (Sepantronium Bromide) purchased from Selleck.

    Western blot analysis of Survivin. U-251 and PC-3 cell line was treated with 0-100nM YM-155.

     

     

    Dr. Chunrong Yu of RoswelI Park Cancer Institute. YM155 (Sepantronium Bromide) purchased from Selleck.

Purity & Quality Control

Choose Selective Survivin Inhibitors

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[2SIg4OiCq MXLEUXNQ M4r6OGlEPTB;MD6wNFkhyrFiMD6wNFA6KM7:TR?= NWHEUno3OjV4NUm3N|E>
M-07e NVPYVodnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvHN3ExPzJiaB?= NX64cGM5TE2VTx?= M4DFR2lEPTB;MD6wOFAhyrFiMD6wNVMh|ryP MlzrNlU3PTl5M{G=
THP-1 NFfPfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYq3NkBp MoLzSG1UVw>? NEjOTnJKSzVyPUCuNFUyKMLzIECuNFE{KM7:TR?= NHnORVIzPTZ3OUezNS=>
CMK NFrlWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jEe|czKGh? MkLqSG1UVw>? NILPOXNKSzVyPUCuNFU{KMLzIECuNFA6KM7:TR?= MX2yOVY2QTd|MR?=
MV4-11 M1vQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H4W|czKGh? M1HwWmROW09? NYTCT|dOUUN3ME2wMlA2PSEEsTCwMlAzQCEQvF2= MXyyOVY2QTd|MR?=
AML-193 MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPXO|IhcA>? MlKzSG1UVw>? Mn\hTWM2OD1yLkS2NkDDuSByLkC2NEDPxE1? MXKyOVY2QTd|MR?=
HL-60 NVrlfYZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPuT|U4OiCq MoXTSG1UVw>? NFvJWYlKSzVyPUCuNFAyKMLzIECuNFAxOiEQvF2= Mn7pNlU3PTl5M{G=
ML-2 NVrOUJpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHncIM5PzJiaB?= NF25dm5FVVOR MV3JR|UxRTBwMEC5JOKyKDBwMECyJO69VQ>? MmrSNlU3PTl5M{G=
OCI/AML3 M37yNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorLO|IhcA>? NV3Pd5BHTE2VTx?= M4rpW2lEPTB;MD6wNVEhyrFiMD6wNFIh|ryP MWKyOVY2QTd|MR?=
HEL NEnIeYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfiZ4U3PzJiaB?= NH\JNGJFVVOR MmDBTWM2OD1yLkW1PUDDuSByLkCzPEDPxE1? NEm2c3EzPTZ3OUezNS=>
ME-1 NVzmPZA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofwO|IhcA>? NXHHfVRITE2VTx?= MYHJR|UxRTBwNki0JOKyKDBwMUe5JO69VQ>? Ml7aNlU3PTl5M{G=
THP-1 NIm4VnFCeG:ydH;zbZMhSXO|YYm= M{i3VVHDqM7:TR?= NVG0eXVkPzJiaB?= M{O2W2ROW09? NH;1[YRqdmS3Y3XzJIFxd3C2b4Ppdy=> NXrkT2txOjV4NUm3N|E>
M-07e Mnn2SpVv[3Srb36gRZN{[Xl? MWCw5qCUOcLizszN M2DH[|czKGh? M{\SSmROW09? MmXPbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= NHrFT2czPTZ3OUezNS=>
THP-1 NEHDRW5HfW6ldHnvckBCe3OjeR?= NFvlfWox6oDVMdMg{txO MlflO|IhcA>? MVLEUXNQ NEH1bZlqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu NYKxcWdROjV4NUm3N|E>
CMK MkDqSpVv[3Srb36gRZN{[Xl? Mn3LNQKBmzIEoN88US=> MVO3NkBp M4TLVGROW09? M2nFfYlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= NHvnNHozPTZ3OUezNS=>
AML-193 MYjGeY5kfGmxbjDBd5NigQ>? MVWw5qCUOcLizszN MkXWO|IhcA>? M3rLbWROW09? M1vaWYlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= Ml3QNlU3PTl5M{G=
Kasumi-1 MUXGeY5kfGmxbjDBd5NigQ>? MXGw5qCUOcLizszN MnzrO|IhcA>? MV;EUXNQ MX3pcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw MlHDNlU3PTl5M{G=
MV4-11 Mn3wSpVv[3Srb36gRZN{[Xl? MXSw5qCUOcLizszN MmjqO|IhcA>? MW\EUXNQ M1\zO4lv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= NGjZSHAzPTZ3OUezNS=>
MUG-Chor  NXv1RmQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnJNE02KM7:TR?= NITKZoQzPC92ODDo MmDTTWM2OD15LkC15qCKdk1iZn;yJFQ5cA>? MX:yOVY1ODF6NR?=
U-CH1  MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTyNE02KM7:TR?= MmTmNlQwPDhiaB?= NWLHS3JHUUN3ME25MlA{6oDLbl2g[o9zKDR6aB?= MofsNlU3PDBzOEW=
KATOIII MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2xNE8zOCCwTR?= MYK0PEBp NXLhPYFxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYWyOVY{PTB3NR?=
AGS  M2HGTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXuRY57OTBxMkCgcm0> NGHtUnU1QCCq MXPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWOyOVY{PTB3NR?=
SACC-83 MYjGeY5kfGmxbjDBd5NigQ>? NIK5V3Q2KG6P MlHaOFghcA>? NEfmWHhl\WO{ZXHz[ZMhdnWlbHXhdkBmgHC{ZYPzbY9vKG:oIFjJSk0y|rF? MX2yOVQ5PTZ|NR?=
INA-6 M3Gwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDMZ|cxNTVyMDDuUS=> MkTzOFghcA>? MVXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mnu4NlUzQTZ7N{i=
U-266 NVHXc|JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWiwMVUxOCCwTR?= M3XYNlQ5KGh? MmTrbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWKyOVI6Pjl5OB?=
MOLP-8 MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXzXVJIOC13MECgcm0> NWS3bphoPDhiaB?= NVPWZpNTcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mn3RNlUzQTZ7N{i=
HG-1 NXL6U4ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\O[moxNTVyMDDuUS=> M4fmUlQ5KGh? M2q5colvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2K1bVI2Ojl4OUe4
NCI-H929 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHOWI8xNTVyMDDuUS=> NHXCfmk1QCCq NXm3XW1kcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIL1T|AzPTJ7Nkm3PC=>
OPM-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC0NE02ODBibl2= MYO0PEBp NHPyVYhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnLGNlUzQTZ7N{i=
L-363 MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVmwMVUxOCCwTR?= MoXQOFghcA>? NV;wcFdwcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXKyOVI6Pjl5OB?=
MOLP-2 NHvP[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHTO4YxNTVyMDDuUS=> MUi0PEBp NULlTXM{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYqyOVI6Pjl5OB?=
KMS-12-BM NUX5ToNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\rZlB1OC13MECgcm0> MkjIOFghcA>? NYfCRZlpcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NG\vT28zPTJ7Nkm3PC=>
SK-MM-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVu1c25ROC13MECgcm0> NU\qW49jPDhiaB?= NUDBO4hbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2PQWFI2Ojl4OUe4
U-266 NIDLfJlCeG:ydH;zbZMhSXO|YYm= MX6wMVUxKG6P MX[yOEBp MmGybY5lfWOnczDhdI9xfG:|aYO= MXWyOVI6Pjl5OB?=
INA-6  MlnmRZBweHSxc3nzJGF{e2G7 MYqwMVUxKG6P NHvqRoMzPCCq MYPpcoR2[2W|IHHwc5B1d3Orcx?= NV7xfGo1OjV{OU[5O|g>
MCF7 M4nZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\ZNlczKGh? MVTJR|UxRTF|INMxJFYhdk1? MlrINlUzOjB{MkW=
MCF7-TamR6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHib|VVPzJiaB?= NYK1c3dLUUN3ME24JOKyKDZibl2= MlrqNlUzOjB{MkW=
MCF7-TamR7 M2rlVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nTW|czKGh? MWnJR|UxRThiwsGgN{BvVQ>? NXvleZZ1OjV{MkCyNlU>
MCF7-TamR8 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID2NmI4OiCq NGnXdWJKSzVyPUG1JOKyKDZibl2= M2n0clI2OjJyMkK1
MCF7-TamC3 MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYG3NkBp MVrJR|UxRTZiwsGgN{BvVQ>? MlPTNlUzOjB{MkW=
MCF7-TamC6 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUftfVhtPzJiaB?= MkHyTWM2OD14INMxJFAvOSCwTR?= NILlcGszPTJ{MEKyOS=>
MDA-MB-231 NIjHU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn6O|IhcA>? MYXJR|UxRTViwsGgNUBvVQ>? M3f3O|I2OjJyMkK1
SK-BR-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rnd|czKGh? NEHuZpJKSzVyPUegxtEhOC5|IH7N M1nXNFI2OjJyMkK1
Eca109 M{DlTGZ2dmO2aX;uJGF{e2G7 NUnJdYR7OS13MDDuUS=> NYDvS3pZPDhiaB?= NEjGbWJFVVOR M2nMTpN2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? Ml[1NlUyOzl|OUW=
TE13 MmTlSpVv[3Srb36gRZN{[Xl? NUXCV2RSOS13MDDuUS=> NVvQeZZtPDhiaB?= NIXqbHlFVVOR M2XtW5N2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NV3sTlc4OjVzM{mzPVU>
Eca109 NFGwUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfH[GRXOC1zMECgcm0> Mn7ONlQwPDhiaB?= NG\GTVNFVVOR NHjYfI1l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NF:2S4QzPTF|OUO5OS=>
TE13 MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2wMVExOCCwTR?= NGP2WZQzPC92ODDo MnXNSG1UVw>? NGezZmtl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NVHEU3RKOjVzM{mzPVU>
MT-3 Mme2T4lv[XOnIFHzd4F6 MkLuO|IhcA>? NY\mV|BmTE2VTx?= MWLJR|UxRTJwOE[gxtEhOC53NDDuUUBnd3JiRGK0JIV5eHKnc4Ppc44> MWKyOFg3PjV6NR?=
MDA-MB-468 NIL0dYRMcW6jc3WgRZN{[Xl? Mn;XO|IhcA>? Mn31SG1UVw>? M{H3[2lEPTB;MD6xNUDDuSByLkCxJI5OKG[xcjDEVlQh\XiycnXzd4lwdg>? M1nlVFI1QDZ4NUi1
SUM-159 NGf2R4pMcW6jc3WgRZN{[Xl? MV23NkBp NIfyeINFVVOR NFGyV49KSzVyPUGuO|IhyrFiMD6zN{BvVSCob4KgSHI1KGW6cILld5Nqd25? MnHDNlQ5PjZ3OEW=
MT-3 NFHyRo5McW6jc3WgRZN{[Xl? NH7CdFU4OiCq MVfEUXNQ NHvXS3lKSzVyPUW0MlEyKMLzIESuN|Ihdk1iZn;yJGRTPSCneIDy[ZN{cW:w NHTKRXczPDh4NkW4OS=>
MDA-MB-468 MYfLbY5ie2ViQYPzZZk> MWW3NkBp M{\3bGROW09? NXPvSYxlUUN3ME2wMlA4KMLzIECuNFIhdk1iZn;yJGRTPSCneIDy[ZN{cW:w MV[yOFg3PjV6NR?=
SUM-159 MkHtT4lv[XOnIFHzd4F6 M1X0R|czKGh? MUfEUXNQ NHn6WYVKSzVyPU[5MlQhyrFiND6yN{BvVSCob4KgSHI2KGW6cILld5Nqd25? NIW2dIczPDh4NkW4OS=>
MT-3 + NAC NYLnbGVLU2mwYYPlJGF{e2G7 MV[3NkBp NWrFbVZ2TE2VTx?= Mny5TWM2OD13Nj6yJOKyKDJwMEegcm0h\m:{IFTSOUBmgHC{ZYPzbY9v Mkj3NlQ5PjZ3OEW=
MT-3 + SB203580 MVfLbY5ie2ViQYPzZZk> M1LWSFczKGh? M{nCNGROW09? M1XMeWlEPTB;M{iuOFEhyrFiNT6wNkBvVSCob4KgSHI2KGW6cILld5Nqd25? MXeyOFg3PjV6NR?=
DB NXvrTGdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTyNVAhdk1? MknLNlQhcA>? NVv3bHc5TE2VTx?= MnPXbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u NXHZNoNGOjR2OE[1PVU>
SU-DHL-8 M{T6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXQRnNYOTBibl2= NITtdmMzPCCq NFHoO2FFVVOR M1XwZYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvci=> MmXQNlQ1QDZ3OUW=
WSU-DLCL2 NULiTYVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT3cVMyOCCwTR?= M4i0XlI1KGh? MYfEUXNQ MWjpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= Ml3qNlQ1QDZ3OUW=
ACC-2 NVLzXmFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYKwMVExOCCwTR?= M3jaXlI1KGh? M1fQSIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MoGwNlQ{PzB7OUW=
ACC-2 NX[4UG51SXCxcITvd4l{KEG|c3H5 NFPzbnUxNTJyIH7N MnLINlQhcA>? M1XKVIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MlTmNlQ{PzB7OUW=
ACC-2 NWf4T5FmTnWwY4Tpc44hSXO|YYm= NFnaWIgxNTJyIH7N MnLaNlQhcA>? M1S1dIlv[3KnYYPld{B1cGViY3;ueoVze2mxbjDv[kBNSzOLIITvJGxEO0mL M1PjWlI1OzdyOUm1
BFTC905 M3PXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne5NE0yODByIH7N NHXwdGI1QCCqwrC= MY\EUXNQ M17TRWlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYrG[|BIOjR{OUe2OFQ>
T24 NFWz[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX2wMVExODBibl2= NXLKelNbPDhiaNMg Ml\LSG1UVw>? NFe0OWpKSzVyPUKwJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXiyOFI6PzZ2NB?=
TSGH8301  NVvmWGMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHwcYsxNTFyMECgcm0> M4HLSlQ5KGkEoB?= M3fkPWROW09? M4[0eWlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mn34NlQzQTd4NES=
BFTC909 NGq5ZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHEeJAxNTFyMECgcm0> NIftdJA1QCCqwrC= MoK2SG1UVw>? M{fxcmlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4TyW|I1Ojl5NkS0
BFTC905 MUjBdI9xfG:|aYOgRZN{[Xl? M4noUlIxKG6P M1rEUFQ5KGh? M4e2R2ROW09? M3[5XYlv\HWlZYOgZZBweHSxc3nz NVrPfnNOOjR{OUe2OFQ>
BFTC905 M3fHfmZ2dmO2aX;uJGF{e2G7 MUiyNEBvVQ>? MVy0PEBp MmnqSG1UVw>? NGTOepdl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVEN|Qj3JTS=> NFH1R4gzPDJ7N{[0OC=>
A2780p MmLJSpVv[3Srb36gRZN{[Xl? Mnf6NE0yODBibl2= MlHiNlQhcA>? M1LsW2ROW09? MoDobY5lfWOnczDTeZJ3cX[rbjDkc5dvemWpdXzheIlwdsLi Mn;YNlQzPjJ6N{W=
A2780cis NXfPXGd4TnWwY4Tpc44hSXO|YYm= MUOwMVExOCCwTR?= NH3ufpQzPCCq NEnKXYhFVVOR NWi5eJJ1cW6mdXPld{BUfXK4aY\pckBld3ewcnXneYxifGmxbtMg NH\Yfo4zPDJ4Mki3OS=>
A2780p MV3BdI9xfG:|aYOgRZN{[Xl? MXu1MVExOCCwTR?= M3fQfVI1NzR6IHi= M3H4PWROW09? M3fY[Ylv[3KnYYPld{BieG:ydH;zbZMhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> M{XZXFI1OjZ{OEe1
A2780cis Mor6RZBweHSxc3nzJGF{e2G7 MYm1MVExOCCwTR?= MlfKNlQwPDhiaB?= MlO5SG1UVw>? MkPTbY5kemWjc3XzJIFxd3C2b4Ppd{BqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MY[yOFI3Ojh5NR?=
SH-SY5Y M2rWTWFxd3C2b4Ppd{BCe3OjeR?= NX;IU45OOS9zMD:xNFAhyrWP MVu3NkBp NE\Nem9FVVOR M2rYPIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3nlN|I1OjV2NU[w
HL-60 NFTG[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjB[IQ4OsLiaB?= NWrJR5puTE2VTx?= NH3EUnhKSzVyPUCuN{BvVQ>? NEC3coYzOzZzOEi2Ni=>
U937  NF\P[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXsZ3A4OsLiaB?= NGXEVVlFVVOR NVrMfG54UUN3ME2wMlghdk1? M1jCblI{PjF6OE[y
HL-60  NGXUXFdHfW6ldHnvckBCe3OjeR?= M3izR|HDqM7:TR?= MUO2M|EzNzJ2IHi= M1XTbWROW09? MnnnbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gd5Vzfmm4aX6= MYSyN|YyQDh4Mh?=
U937  MnnYSpVv[3Srb36gRZN{[Xl? MVexxsDPxE1? NXHNNXlMPi9zMj:yOEBp NXqzXVJWTE2VTx?= MXvpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDzeZJ3cX[rbh?= M{HRTVI{PjF6OE[y
HL-60 M2\zb2Fxd3C2b4Ppd{BCe3OjeR?= MW[wMlEwOSEQvF2= MXi4JIg> MV;EUXNQ MmfQbY5lfWOnczDhdI9xfG:|aYO= MnnkNlM3OTh6NkK=
Sk-NEP-1  NFzqeZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjWNU0yODByMDDuUS=> M{XkO|I1KGh? NX;kXYJuTE2VTx?= NE\MTFRKSzVyPUGwNEBvVQ>? MX6yN|I3PzZ7OR?=
SK-NEP-1  NXHXbVRUSXCxcITvd4l{KEG|c3H5 NF7NXYU2OC9zMECgcm0> MWKxNk8zPCCq MXfEUXNQ M2LSZ4lv\HWlZYOgZZBweHSxc3nz Ml;SNlMzPjd4OUm=
TC-32 NVn4ellIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUWwMlEuOTByMDDuUS=> MYjFR|UxRTNwMDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEHPT2YzOjl4MUe2Ny=>
TC-71 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfZNE4yNTFyMECgcm0> MYfFR|UxRTVwNzDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NH:0OoIzOjl4MUe2Ny=>
SK-ES-1 MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTidG9XOC5zLUGwNFAhdk1? NEX4fYtGSzVyPUKuPEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NWjCc2ZLOjJ7NkG3OlM>
RD-ES MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:wMlEuOTByMDDuUS=> MoXMSWM2OD14LkKgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2mwfFIzQTZzN{[z
HEK293 NVzVPXg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPZW2UxNjFvMUCwNEBvVQ>? MoCxSWM2OD1{Mz6wJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2LTPFIzQTZzN{[z
M059J NF7EdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPRblYxNTVyIH7N MUC0PEBp M17WWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mn:4NlI4PzBzMUC=
M059K NV3T[YhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[2dHMxNTVyIH7N NXLwcGx6PDhiaB?= M3fLO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4n2cVIzPzdyMUGw
M059J NFTKeVFCeG:ydH;zbZMhSXO|YYm= M2TBb|MxKG6P NFLq[JYzPCCq NXTmNFJlcW6mdXPld{BieG:ydH;zbZM> M{jPS|IzPzdyMUGw
M059K M1LNemFxd3C2b4Ppd{BCe3OjeR?= NWfBSIFLOzBibl2= MlexNlQhcA>? NXLMR3F2cW6mdXPld{BieG:ydH;zbZM> MXuyNlc4ODFzMB?=
PANC-1 NYqzdpd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPxNE4xOS1zMECwJI5O NHK5O3I1QCCq NIXqdWdKSzVyPUOuOlkhdk1? NY\OZZVXOjJ5MkO4O|E>
MIAPaCa-2 NF\aUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\xPYYxNjBzLUGwNFAhdk1? MYe0PEBp NH[4Xo1KSzVyPUK5MlM3KG6P M{[2OVIzPzJ|OEex
BxPC-3 MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX63[|lDOC5yMT2xNFAxKG6P NG\6[FY1QCCq Ml\vTWM2OD1|MD6yOkBvVQ>? NYXuSJdOOjJ5MkO4O|E>
PANC-1 M3vldWZ2dmO2aX;uJGF{e2G7 MX2wMVExODBibl2= NF;tN5MzPCCq NEnj[llqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHhKSVBiYX7kJJN2en[rdnnuJIV5eHKnc4Ppc44> MUmyNlczOzh5MR?=
MIAPaCa-2 NHfTbmRHfW6ldHnvckBCe3OjeR?= M1;Q[VAuOTByMDDuUS=> NWfRO4kzOjRiaB?= MUTpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGjJRXAh[W6mIIP1dpZqfmmwIHX4dJJme3Orb36= MV[yNlczOzh5MR?=
BxPC-3 MlrFSpVv[3Srb36gRZN{[Xl? MYiwMVExODBibl2= MoWzNlQhcA>? MVfpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGjJRXAh[W6mIIP1dpZqfmmwIHX4dJJme3Orb36= NULBTYhzOjJ5MkO4O|E>
RPMI-7951 M{nXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLRVHVQT0l3ME2zMlIhdk1? M37VZlIyPzN5NUCy
SK-MEL-5 M2fzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmG2S2k2OD12LkKgcm0> NFvyOHQzOTd|N{WwNi=>
A375 NGLLclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[4RWFlT0l3ME22MlMhdk1? NUXZPG9DOjF5M{e1NFI>
SK-MEL-28 NVzkRpR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37MNWdKPTB;Nz62JI5O MnXWNlE4Ozd3MEK=
SK-MEL-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO1R5p2T0l3ME2xNUBvVQ>? M1n3c|IyPzN5NUCy
DB M2XqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\L[XU1QMLiaB?= NIOyVotIUTVyPUOuOUBvVQ>? M3LhW|IyOjN5NUC4
Pfeiffer Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HuXlQ5yqCq MnrXS2k2OD1|Lkmgcm0> NX;GfoNTOjF{M{e1NFg>
SU-DHL-5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT6dXprPDkEoHi= NVTP[GduT0l3ME2wMlI{KG6P MWSyNVI{PzVyOB?=
SU-DHL-8 NVLoPY5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkntOFjDqGh? MoruS2k2OD1zLkSgcm0> MWmyNVI{PzVyOB?=
WSU-DLCL-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3W1b|Q5yqCq M{m1WGdKPTB;MT60JI5O NYjWV49xOjF{M{e1NFg>

... Click to View More Cell Line Experimental Data

In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Promoter-luciferase reporter assay:

A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5
Cell Research:

[1]

+ Expand
  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Formulation: Dissolved and diluted in saline immediately before administration
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
    (Only for Reference)

Solubility (25°C)

In vitro Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol 6 mg/mL (13.53 mM)
In vivo Saline 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01100931 Completed NSCLC|Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 2010 Phase 1|Phase 2
NCT01038804 Completed Breast Cancer Astellas Pharma Inc December 2009 Phase 2
NCT01023386 Completed Cancer Astellas Pharma Inc November 2009 Phase 1
NCT01009775 Completed Melanoma Astellas Pharma Inc November 2009 Phase 2
NCT01007292 Completed Non-Hodgkins Lymphoma Astellas Pharma Inc November 2009 Phase 2
NCT00498914 Terminated Lymphoma, Large-Cell, Diffuse|Lymphoma, B-Cell Refractory Astellas Pharma Inc June 2007 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Survivin Signaling Pathway Map

Related Survivin Products

Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID